Renal fibrosis is characterised by an excessive accumulation of extracellular matrix (ECM) proteins. Evidence suggests that this results from both increased ECM synthesis and a reduced degradation. Here, we determine changes in the matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP) in relation to ECM production and the progression of renal fibrosis in subtotally nephrectomized (SNx) rats. Groups of 4–6 SNx or sham-operated male Wistar rats were sacrificed between days 7 and 120 following surgery. Total RNA was analysed by Northern blotting. Messenger RNA for collagens I (+710%), III (+674%), and IV (+358%) were significantly (p < 0.05) raised by day 7 and remained elevated over the 120 days. Significant (p < 0.05) increase in fibronectin, laminin and heparan sulfate proteoglycan mRNAs occurred latter at days 60 (+224%), 120 (+210%), and 120 (+256%), respectively. Increases (p < 0.05) in mRNA for MMP-1 (+360%) and MMP-2 (+239%) occurred from day 7 with MMP-1 reaching +881% by day 120. MMP-3 and -9 showed no change. Zymography on day 90 remnant kidneys showed mRNA changes were translated into active MMP-1 (+1,700%) and MMP-2 (+440%), p < 0.05. TIMP-1 mRNA was also raised (+548%, p < 0.05) by day 7 and remained elevated, while TIMP-2 mRNA levels only reached significance by day 120 (+165%). In contrast, TIMP-3 mRNA was decreased by day 30 (p > 0.05) and dropped to 27% of control by day 120. However, Western blot analysis of TIMPs 1 and 3 at day 90 showed a 5- and 4-fold increase respectively, while TIMP-2 levels were not significantly altered. Measurements of overall collagenase activities in remnant kidney homogenates were reduced. Using collagen I and IV substrates, proteolytic activity in remnant kidneys dropped to 40 and 27% of controls (p < 0.01), respectively. This data suggests that reduced MMP activity may contribute towards renal scarring, however this is not a result of reduced MMP transcription or activation, but likely to be due to the inhibition by TIMPs.

Keywords:
MMP, TIMP, Renal, Fibrosis, Extracellular matrix, Zymography, Collagenase
1.
Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997;51:2–15.
2.
Thomas GL, Yang B, Wagner BE, Savill J, El Nahas AM: Cellular apoptosis and proliferation in experimental renal fibrosis. Nephrol Dial Transplant 1998;13:2216–2226.
3.
Nath KA: The tubulointerstitium in progressive renal disease. Kidney Int 1998;54:992–994.
4.
Lenz O, Elliot SJ, Stetler-Stevenson WG: Matrix Metalloproteinases in renal development and disease. J Am Soc Nephrol 2000;11:574–581.
5.
Jones CL: Matrix regulation in renal disease. Nephrology 1996;2:13–23.
6.
Davies M, Martin J, Thomas GJ, Lovett DH: Proteinases and glomerular matrix turnover. Kidney Int 1992;41:671–678.
7.
Floege SJ, Johnson RJ, Gordon K, Yoshimura A, Cambell C, Iruea-Aripse L, Alpers CE, Couser WG: Altered glomerular extracellular matrix synthesis in experimental membranous nephrology. Kidney Int 1992;42:573–585.
8.
Peten EP, Stricker LJ, Carome MA, Elliott SJ, Yang CW, Striker GE: The contribution of increased collagen synthesis to human glomerulosclerosis: A quantitative analysis of α(2) IV collagen mRNA expression by competitive polymerase chain reaction. J Exp Med 1992;176:1571–1576.
9.
Eddy AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996;7:2495–2508.
10.
Norman JT, Lewis MP: Matrix Metalloproteinases in Renal Fibrosis. Kidney Int 1996;49:S61–S63.
11.
Engelmyer E, van-Goor H, Edwards DR, Diamond JR: Differential mRNA expression of renal cortical tissue inhibitor of metalloproteinase-1, -2 and -3 in experimental hydronephrosis. J Am Soc Nephrol 1995;5:1675–1683.
12.
Arthur JPM: Fibrosis and altered matrix degradation. Digestion 1998;59:376–380.
13.
Coker ML, Thomas CV, Clair MJ, Hendrick JW, Krombach RS, Galis ZS, Spinale GF: Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol 1998;274:H1516–H1523.
14.
Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493–2503.
15.
Swinderski RE, Dencoff JE, Floerchinger CS, Shapiro SD, Hunninghake GW: Differential expression of extracellular matrix remodelling genes in a murine model of bleomycin induced pulmonary fibrosis. Am J Pathol 1998;152:821–828.
16.
Poncelet AC, Schnaper: Regulation of human mesangial cell collagen expression by transforming growth factor-beta1. Am J Physiol 1998;275:F458–F466.
17.
Martin J, Steadman R, Knowlden J, Williams J, Davies M: Differential regulation of matrix metalloproteinases and their inhibitors in human glomerular epithelial cells in vitro. J Am Soc Nephrol 1998;9:1629–1637.
18.
Baricos WH, Cortez SL, Deboisblanc M, Xin S: Transforming growth factor-beta ins a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 1999;10:790–795.
19.
Johnson DW, Saunders HJ, Baxter RC, Field MJ, Pollock CA: Paracrine stimulation of human renal fibroblasts by proximal tubule cells. Kidney Int 1998;54:747–757.
20.
Douthwaite JA, Johnson TS, Haylor JH, El Nahas AM: Effects of transforming growth factor-β1 on renal extra-cellular matrix components and their regulating proteins. J Am Soc Nephrol 1999;10:2109–2119.
21.
Norman JT, Gatti L, Wilson PD, Lewis M: Matrix metalloproteinases and tissue inhibitor of matrix metalloproteinase expression by tubular epithelial and interstitial fibroblasts in the normal kidney and in fibrosis. Exp Nephrol 1995;3:88–89.
22.
Schnaper HW, Kopp JB, Poncelet AC, Hubchak SC, Stetler-Stevenson WG, Klotman PE, Kleinman HK: Increased expression of extracellular matrix proteins and decreased expression of matrix proteases after serial passage of glomerular mesangial cells. J Cell Sci 1996;109:2521–2528.
23.
Gonzalez-Avila AG, Iturria C, Vadillo-Ortega F, Ovalle C, Montano M: Changes in matrix metalloproteinases during the evolution of interstitial renal fibrosis in a rat experimental model. Pathobiology 1998;66:196–204.
24.
Duymelinck C, Deng JT, Dauwe SEH, De Broe ME, Verpooten GA: Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy. Kidney Int 1998;54:804–818.
25.
Schafer L, Lorenz T, Daemmrich J, Heidland A, Schaefer RM: Role of proteinase in renal hypertrophy and matrix accumulation. Nephrol Dial Transplant 1995;10:801–807.
26.
Johnson TS, Griffin M, Thomas GL, Skill NJ, Cox A, Yang B, Nicholas B, Birckbichler PJ, Kubara Cand El Nahas AH: The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. J Clin Invest 1997;99:2950–2690.
27.
Schwarbauer JE, Tamkun JN, Lemischka IR, Hynes RO: Three different fibronectin mRNAs arise by alternative splicing within the coding region. Cell 1983;35:421–431.
28.
Barlow DP, Green NM, Kurkinen M, Hogan BLM: Sequencing of laminin B chain cDNAs reveals C terminal regions of homology. Coiled coil alpha helix. EMBO J 1984;3:2355–2362.
29.
Vuorio T, Makela JK, Kahari VM, Vuorio E: Coordinated regulation of type I and III collagen production and messenger RNA levels of pro-alpha-1(I) and pro-alpha-2(I) collagen in cultured morphea fibroblasts. Arch Dermatol Res 1987;279:154–160.
30.
Virolainen P, Perala M, Vuorio E, Aro HT: Expression of matrix genes during incorporation of cancellous bone allografts. Clin Orthopead Rel Res 1995;317:263–272.
31.
Kurkinen M, Condon MR, Blumberg B, Barlow DP, Quinones S, Saus J, Pihlajanniemi T: Extensive homolgy between the carboxy-terminal peptides of mouse α1(IV) and α2(IV) collagen. J Biol Chem 1987;262:8496–8499.
32.
Kallunki P, Eddy RL, Byers MG, Kestila M, Shows TB, Trygvason K: The cloning of human heparin sulphate proteoglycan core protein, assigment of the gene (HSPG2) to 1p36.1→p35 and identification of Bam H1 restriction fragment polymorphism. Genomics 1991;11:389–396.
33.
Iredale JP, Benyon RC, Arthur MPJ, Ferris WF, Alcolado R, Winwood PJ, Clark N, Murphy G: Tissue inhibitors of metalloproteinase 1 mRNA expression is enhanced relative to interstitial collagenase mRNA in experimental liver injury and fibrosis. Hepatology 1996;24:176–184.
34.
Cook TF, Burke JS, Bergman KD, Quinn CO, Jeffrey JJ, Partridge NC: Cloning and regulation of rat tissue inhibitor metalloproteinase 2 in osteoblastic cells. Arch Biochem Biophys 1994;311:313–320.
35.
Uria JA, Ferrando AA, Velasco G, Freije JMP, Lopez-Otin C: Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res 1994;54:2091–2094.
36.
Marti HP, Mc Neil L, Davies M, Martin J, Lovett DH: Homology cloning of 72 kDa type IV collagenase – cytokine and 2nd messenger inducibility in glomerular mesangial cells. Biochem J 1993;291:441–446.
37.
Quinn CO, Scott DK, Brinckeroff CE, Martisian LM, Jeffrey JJ, Partridge NC: Rat collagenase: Cloning, amino acid sequence comparison and parathyroid regulation in osteoblastic cells. J Biol Chem 1990;265:22342–22347.
38.
Eddy AA, Kim H, Lopez-Guisa J, Oda T, Soloway PD: Interstitial fibrosis in mice with overload proteinuria: Deficiency of TIMP 1 is not protective. Kidney Int 2000;58:618–628.
39.
Kim H, Oda T, Lopez-Guisa J, Wing D, Edwards D, Soloway P, Eddy AA: TIMP 1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2000;11:531A.
40.
Wu I, Mosses MA: Cloning and expression of the cDNA encoding rat tissue inhibitor of metalloproteinase 3. (TIMP 3). Gene 1996;168:243–246.
41.
Oda T, Jung YO, Kim H, Lopez Guisa J, Cai X, Ikeda Y, Eddy AA: PAI-1 deficiency attenuates renal interstitial fibrosis in mice with obstructive uropathy. J Am Soc Nephrol 2000;11:535A.
42.
Langton KP, Barker MD, McKie N: Localization of the functional domains of human tissue inhibitor of metalloproteinase-3 and the effects of a Sorsby’s fundus dystrophy mutation. J Biol Chem 1998;273:16778–16781.
43.
Bungo M, Witek B, Bereta M, Edwards DR, Kordula T: Reprogramming of TIMP-1 and TIMP-3 expression profiles in brain microvascular endothelial cells and astrocytes in response to proinflammatory cytokines. FEBS Lett 1999;448:9–14.
44.
Li YY, McTiernan CF, Feldman AM: Proinflammatory cytokines regulate tissue inhibitors of metalloproteinase and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res 1999;42:162–172.
45.
Su S, DiBattista JA, Sun Y, Li WQ, Zafarullah M: Up-regulation of tissue inhibitor of metalloproteinase-3 gene expression by TGF-beta in articular chondrocytes is mediated by serine/threonine and tyrosine kinases. J Cell Biochem 1998;70:517–527.
46.
Huang HY, Wen Y, Irwin JC, Kruessel JS, Soong YK, Polan ML: Cytokine-mediated regulation of 92-kDa type IV collagenase, tissue inhibitor or metallproeinase-1 (TIMP-1), and TIMP-3 messenger ribonucleic acid expression in human endometrial stromal cells. J Clin Endocrinol Metab 1998;83:1721–1729.
47.
Mattila L, Airola K, Ahonen M, Hietarinta M, Black C, Saarialho-Kere U, Kahari VM: Activation of tissue inhibitor of metallproteinase-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol 1998;110:416–421.
48.
Mozes MM, Bottinger EP, Jacot TA, Kopp JB: Renal expression of fibrotic matrix proteins and of transforming growth factor beta (TGF) isoforms in TGF-beta transgenic mice. J Am Soc Nephrol 1999;10:271–280.
49.
Castagnino P, Soriano JV, Montesano R, Bottaro DP: Induction of tissue inhibitor of metalloproteinase-3 is a delayed early cellular response to hepatocyte growth factor. Oncogene 1998;17:481–492.
50.
Andreu T, Beckers T, Thoenes E, Hilgard P, von Melchner H: Gene trapping identifies inhibitors of oncogenic transformation. The tissue inhibitor of metalloproteinase-3 (TIMP-3) and collagen type I alpha2 (COL1A2) are epidermal growth factor-regulated growth repressors. J Biol Chem 1998;273:13848–13854.
51.
Pickering JG, Ford CM, Tang B, Chow LH: Coordinated effects of fibroblast growth factor-2 on expression of fibrillar collagens, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinases by human vascular smooth muscle cells. Evidence for repressed collagen production and activated degradative capacity. Arterioscler Thromb Vasc Biol 1997;17:475–482.
52.
Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR: Tissue inhibitor of metalloproteinase-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994;269:9352–9360.
53.
Selman M, Ruiz V, Cabrera S, Segura L, Ramirez R, Barrios R, Pardo A: TIMP-1, -2, -3 and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol 2000;279:L562–574.
54.
Yang B, Johnson TS, Thomas GL, Watson PF, Wagner B, Skill NJ, Haylor JL, El Nahas AM: Expression of apoptosis-related genes and proteins in experimental chronic renal scarring. J Am Soc Nephrol 2001;12:275–288.
55.
Matrisian LN: Metalloproteinase and their inhibitor in matrix remodelling. Trends Genet 1990;6:121–125.
56.
Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJP, Angel P, Heath JK: Transforming growth factor modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987;6:1899–1904.
57.
Wright JK, Cawston TE, Hazleman BL: Transforming growth factor beta stimulates the production of the tissue inhibitor of metalloproteinases (TIMP) by human synovial and skin fibroblasts. Biochim Biophys Acta 1991;1094:207–210.
58.
Fine LG, Norman JT, Ong A: Cell-cell cross talk in the pathogenesis of renal interstitial fibrosis. Kidney Int 1995;47(suppl 49):S48–S50.
59.
Lewis MP, Norman JT: Differential response of activated versus non-activated renal fibroblasts to tubular epithelial cells: A model of initiation and progression of fibrosis? Exp Nephrol 1998;6:132–143.
60.
Muchaneta-Kubara EC, Sayed-Ahmed N, El Nahas AM: Subtotal nephrectomy: A mosaic of growth factors. Nephrol Dial Transplant 1995;10:320–327.
61.
Lewis MP, Fine LG, Norman JT: Pexicrine effects of basement membrane components on paracrine signalling by renal tubular cells. Kidney Int 1996;49:48–58.
62.
Norman JT, Orphanides C, Garcia P, Fine LG: Hypoxia induced changes in extracellular matrix metabolism in renal cells. Exp Nephrol 1999;7:463–469.
63.
Norman J, Stidwill T, Cook T, Singer M, Fine L: Evidence for a progressive decline in tubulo-interstitial oxygenation – a model of rapidly progressive glomerulonephritis: Further support for the chronic hypoxia hypothesis. J Am Soc Nephrol 2000;11:625A.
64.
Yasuda T, Kondo S, Homma T, Harris RC: Regulation of extracellular matrix by mechanical stress in rat glomerular mesangial cells. J Clin Invest 1996;98:1991–2000.
65.
Chesler NC, Ku-David N; Galis-Zorina: Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am J Physiol 1999;277:H2002–H2009.
66.
Schiowa S: Participation of macrophages in glomerular sclerosis through the expression and activation of matrix metalloproteinases. Pathol Int 2000;50:441–457.
67.
Raza S, Benyon RC, Arthur MJP: Cleavage of the cell adhesion molecules CD44 and ICAM-1 by matrix metalloproteinases. Mol Biol Cell 1995;6:961.
68.
Nunes I, Gleizes PE, Metz CN: Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol 1997;136:1151–1163.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.